| Literature DB >> 29116786 |
Olivier Bezençon1, Bibia Heidmann1, Romain Siegrist1, Simon Stamm1, Sylvia Richard1, Davide Pozzi1, Olivier Corminboeuf1, Catherine Roch1, Melanie Kessler1, Eric A Ertel1, Isabelle Reymond1, Thomas Pfeifer1, Ruben de Kanter1, Michael Toeroek-Schafroth1, Luca G Moccia1, Jacques Mawet1, Richard Moon1, Markus Rey1, Bruno Capeleto1, Elvire Fournier1.
Abstract
We report here the discovery and pharmacological characterization of N-(1-benzyl-1H-pyrazol-3-yl)-2-phenylacetamide derivatives as potent, selective, brain-penetrating T-type calcium channel blockers. Optimization focused mainly on solubility, brain penetration, and the search for an aminopyrazole metabolite that would be negative in an Ames test. This resulted in the preparation and complete characterization of compound 66b (ACT-709478), which has been selected as a clinical candidate.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29116786 DOI: 10.1021/acs.jmedchem.7b01236
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446